TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06563700

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: spectacle lens
Description: one of ZEISS BD spectacle lens designs 1 to 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectacle lens
Description: one of ZEISS BD spectacle lens designs 1 to 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectacle lens
Description: one of ZEISS BD spectacle lens designs 1 to 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectacle lens
Description: one of ZEISS BD spectacle lens designs 1 to 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectacle lens
Description: one of ZEISS BD spectacle lens designs 1 to 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectacle lens
Description: one of ZEISS BD spectacle lens designs 1 to 5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: single vision lens
Description: single vision lens
Study: NCT04474080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer Support Platform
Description: The intervention program will consist of 6 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification \& context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Period
Description: The control period will be the time prior to randomization and commencement of the intervention, whereby residents will continue with their regular academic day activities during the allotted intervention time
Study: NCT05432726

Intervention type: OTHER
Intervention: calculating CARG score
Description: Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored.
Study: NCT05596058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task protocol: active exercises with concomitant cognitive training in executive functions
Description: The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active exercise
Description: Physical activity and motor task only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive task only
Description: cognitive exercise in executive functions
Study: NCT04869228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918 tablets or placebo
Description: GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GT0918 tablets or placebo
Description: GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
Study: NCT05077644

Intervention type: DEVICE
Group type: OTHER
Intervention: Stella (TM) Mobile Application
Description: Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
Study: NCT05342506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + ScTIL
Description: Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
Study: NCT06581211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy and Essential Oils
Description: Inhale LA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba Oil
Description: Inhale jojoba oil aromatherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: Inhale LAO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06581211

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06123325

Intervention type: PROCEDURE
Intervention: Clipping
Description: Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
Study: NCT06123325

Intervention type: PROCEDURE
Intervention: Endovascular embolization
Description: Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.

Intervention type: DIAGNOSTIC_TEST
Intervention: Surveillance imaging
Description: Surveillance imaging for brain aneurysms is a diagnostic approach that uses imaging techniques such as MRI, MRA, CTA, or DSA to regularly monitor the status of detected brain aneurysms. The goal is to track changes in the aneurysm's size, shape, or structure over time, which may indicate an increased risk of rupture. This ongoing assessment helps healthcare providers decide whether to continue monitoring or to consider treatment options, such as surgical clipping or endovascular coiling, based on the aneurysm's characteristics and the patient's risk factors.
Study: NCT05794620

Intervention type: OTHER
Intervention: Stool sample
Description: Stool sample

Intervention type: OTHER
Intervention: Stool sample
Description: Stool sample
Study: NCT04251715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given intraarterially via HAI pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given intraarterially via HAI pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT05037877

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HUM supplement
Description: HUM supplement - 1 capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement - 1 capsule per day
Study: NCT04251715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05234229

Intervention type: OTHER
Intervention: Survey
Description: Collection of immunization status by questionnaire

Intervention type: OTHER
Intervention: Survey
Description: Collection of immunization status by questionnaire
Study: NCT06054282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready for Tonsillectomy educational mobile application
Description: The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions.
Study: NCT06153225

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein products
Description: In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein products
Description: In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
Study: NCT05184023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Electromagnetic Field
Description: Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulse Electromagnetic Field
Description: Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
Study: NCT06087926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes.
Study: NCT05102721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab and Pepinemab
Description: IV Infusions every two weeks.
Study: NCT04728412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen Therapy (HFOT)
Description: HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
Study: NCT05443646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: 45Gy/3Gy/3week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: 25Gy/2.5Gy/2week
Study: NCT04963920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb® 300 ml
Description: patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
Study: NCT05222724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachifene
Description: paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brufen
Description: ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
Study: NCT05406674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 100 mg/m2
Description: Cisplatin 100 mg/m2 milligram(s)/square meter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/l
Description: Cisplatin 40 mg/I milligram(s)/litre
Study: NCT06226649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Dyadic Empowerment
Description: The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers.
Study: NCT06435663

Intervention type: OTHER
Group type: OTHER
Intervention: Different methods of efficacy evaluation
Description: When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different methods of efficacy evaluation
Description: When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
Study: NCT06139276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small Needle-Knife
Description: The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study: NCT05549960

Intervention type: DEVICE
Group type: OTHER
Intervention: The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).
Description: EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present.
Study: NCT05842616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial doppler pulsatility index guided protocol
Description: Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mean arterial blood pressure guided protocol
Description: Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
Study: NCT06009939

Intervention type: OTHER
Intervention: Occlusion of the circulation in the arm and foot
Description: A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.

Intervention type: OTHER
Intervention: Occlusion of the circulation in the arm and foot
Description: A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.

Intervention type: OTHER
Intervention: Occlusion of the circulation in the arm and foot
Description: A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.

Intervention type: OTHER
Intervention: Occlusion of the circulation in the arm and foot
Description: A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
Study: NCT05201547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-Paclitaxel
Description: Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
Study: NCT06092723

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 1,Lactococcus lactis subsp. lactis, LY-66
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 2,Lactobacillus plantarum, PL-02
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 3,Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.
Study: NCT05986955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.
Study: NCT05303220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dose on specified days
Study: NCT04716491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
Description: When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.